Skip to main content Help with accessibility Skip to main navigation

PSORIASIS in adults, sequential use of biological agents

CCG Approval Status:

Date Added: 24 - Feb - 2022
Body System:

The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab, bimekizumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab, in the management of psoriasis according to the attached flowchart.